ASCO Annual Meeting: Bladder Cancer and RCC

Articles

The application for adjuvant pembrolizumab in renal cell carcinoma is supported by data from the phase 3 KEYNOTE-564 trial, which were presented at the 2021 ASCO Annual Meeting. 

FDA grants adjuvant pembrolizumab priority review in kidney cancer

Videos

"There is clearly a lot of interest in the urologic oncology world toward bladder preservation for both muscle-invasive bladder cancer as well as early-stage non-muscle-invasive bladder cancer," says Arjun V. Balar, MD.

Dr. Arjun Balar’s key takeaway from ASCO 2021

Arjun V. Balar, MD, discusses notable findings from 2 separate studies of pembrolizumab (Keytruda).

Pembrolizumab demonstrates efficacy as part of trimodal treatment in bladder cancer 

Arjun V. Balar, MD, describes the 2 “very distinct patient populations” of separate phase 2 studies from ASCO 2021 involving the treatment pembrolizumab (Keytruda).

Dr. Balar discusses the background behind phase 2 studies of pembrolizumab in bladder cancer

Results from a pooled analysis of frontline treatment in metastatic renal cell carcinoma provided early evidence of a differential overall survival benefit between patients with favorable-risk disease compared to patients with intermediate/poor-risk disease.

Risk-group analysis offers clues to optimizing frontline I/O combos in metastatic kidney cancer

“The key message from this abstract is that the time duration for starting avelumab [Bavencio] maintenance didn't really affect the outcomes,” says Shilpa Gupta, MD.

Dr. Gupta discusses avelumab first-line maintenance treatment for advanced urothelial carcinoma

Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.

Metastatic urothelial carcinoma: Is addition of more therapies to treatment regimens beneficial?

"I think [at] the 2021 ASCO annual meeting, we saw a lot of novel data focusing on bladder-preservation approaches," says Shilpa Gupta, MD.

Dr. Gupta discusses bladder cancer research highlights from ASCO 2021

Miron presented a study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on survival outcomes in patients who received immunotherapy in the second-line setting.

Dr. Miron on first-line treatment selection in bladder cancer

In this video, Shilpa Gupta, MD, discusses the rapidly evolving world of research on urothelial carcinoma.